about
Off-label use of rituximab in systemic rheumatic diseases: case series and reviewPrevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey.Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.The Portuguese Society of Rheumatology position paper on the use of biosimilars.DXA in the assessment of subchondral bone mineral density in knee osteoarthritis--A semi-standardized protocol after systematic review.Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.Apolipoprotein E and undercaboxylated osteocalcin are associated with bone fragility but not with bone mineral density in osteoarthritis patients.Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patients.2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?Translation and cross-cultural adaptation of the ASAS Health Index and ASAS Environmental Factors Item Set into European Portuguese Language.EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology.Low osteocalcin/collagen type I bone gene expression ratio is associated with hip fragility fractures.Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program.Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations.Investigator initiated trials in Portuguese rheumatology.Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritisWork participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA studyCotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over timeWhich scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohortCervical spine involvement as initial manifestation of rheumatoid arthritis: a case reportThree handy tips and a practical guide to improve your propensity score models.Normocalcemic primary hyperparathyroidism presenting as calcinosis cutisEfficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritisSafety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisIs treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM CohortEligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAIIs active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohortsPerformance of referral strategies for spondyloarthritis: a population-based nationwide studyResponse to: 'Reactive arthritis, a missing link: comment on the recent article from Sepriano et al' by Zeidler and HudsonRoutine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practiceIs a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohortsOutcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
P50
Q27023679-05C056E1-C40A-4971-8642-27B2DFB4FD5CQ36517265-5B952177-8A5E-4611-A818-D66BB6B27569Q37612248-00C58415-1533-4F83-9AF7-E044799529C8Q38210435-C242A72C-0C9C-4315-9DC7-E1BC3114164DQ38549966-7BC610B3-C532-4629-993F-13412ADC2FAAQ38690333-329E2B2D-3197-42A9-9FC5-FB22112CD70CQ39180660-416F2F62-B8B8-4052-AF64-8174EE4DBC10Q40916807-11C57239-91C1-465D-B07D-91DA9AB19B66Q45851677-447C2664-DB46-4328-B003-4EC6CF7B9303Q47272523-0C7BEB41-CBFE-4D20-80D5-A00C3B950F29Q48049806-8AD8C67A-241B-4762-8D89-331C32B0F03BQ48232568-B05B7E01-F216-4885-A861-B9A3C360CA19Q48597392-B7364E91-DA13-4248-804C-581342F0870AQ50576899-0106A861-7BA7-4793-B209-38AFC71A6F31Q51351458-4842C634-75A7-4CEB-B644-942D8A5FB341Q51714525-46B23263-58B5-4CF0-A2CE-AFE1D641CF5FQ52659242-8E4F1232-8027-4117-8781-67460B69E373Q52659244-05517137-9F25-45F1-B4B2-3024E611D491Q54718635-5525FCA6-2C23-44BA-8EDC-E78183350F72Q56334428-C5FC8B45-170B-45BF-9F67-7739CCD07C9AQ56966334-4DBFF853-83BB-49A0-9BA7-96A6E30208BAQ58220881-870E86E2-E450-4E12-A3D9-24C5020A232AQ61812081-52D52DD9-13C2-4581-A23A-FD0A02F7EF2AQ61882063-475EAE42-FE2A-4AC5-8F6D-BE8AB94EC5AEQ61882068-1CC32D06-C9C5-4F68-AB02-4B818816A4F1Q64889425-1F77C4D9-BFBC-4704-B72D-338666EC07F9Q87666761-0C7AF02E-BBCD-4C3F-9000-6507F4E6B905Q89600836-98D3E6E7-81AC-4377-BC31-72C3BC34D6C5Q89600856-5BB7B9CB-8B4E-4012-A8BF-26529101CFBCQ89865011-D200F409-6735-4E37-819C-AD1F76AF7CA0Q90114830-16810A70-992D-4A08-BAE7-D3021AC861B5Q90117055-A9228E6D-0FAA-4238-B374-EF5A7F6894F5Q90452028-4F521AB2-230A-4185-9381-0C8282F34567Q91072791-FB848BF5-6D49-4C9F-91E6-853F240BD4A2Q91520024-6585967A-DDAE-4DC4-952F-7757E7FFF736Q92463387-C9956435-E8CB-4982-A50E-2BE7198788BFQ92781304-B0FD8D13-01C6-47B2-AB8D-B69F137C0D45Q92931731-D193174E-237A-4157-9EDC-8BDEBFF2181BQ93045479-748C1172-75C0-4C1E-94B3-6270D36853F4Q94586512-D0500093-FF72-42A5-818E-AB47C0E3F5E7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexandre Sepriano
@ast
Alexandre Sepriano
@en
Alexandre Sepriano
@es
Alexandre Sepriano
@nl
Alexandre Sepriano
@pt
Alexandre Sepriano
@sl
type
label
Alexandre Sepriano
@ast
Alexandre Sepriano
@en
Alexandre Sepriano
@es
Alexandre Sepriano
@nl
Alexandre Sepriano
@pt
Alexandre Sepriano
@sl
altLabel
Alexandre R. Sepriano
@en
prefLabel
Alexandre Sepriano
@ast
Alexandre Sepriano
@en
Alexandre Sepriano
@es
Alexandre Sepriano
@nl
Alexandre Sepriano
@pt
Alexandre Sepriano
@sl
P106
P1153
55266526300
P1960
0sEAaR0AAAAJ
P2038
Alexandre_Sepriano
P21
P2798
P31
P496
0000-0003-1954-0229